Introduction
Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) is a key mediator of angiogenesis for both physiological and pathological conditions (Senger et al., 1983 (Senger et al., , 1986 Leung et al., 1989; Folkman and Hanahan, 1991; Dvorak, 2000; Ferrara, 2001 Ferrara, , 2002 Dvorak, 2002; Papetti and Herman, 2002) . The transcriptional regulation of VPF/VEGF expression has been well studied so far. It is known that transcription factors, such as hypoxia inducible factor (HIF) and Sp1, play important roles in VPF/VEGF mRNA transcription (Mukhopadhyay et al., 1997; Maxwell et al., 1999; Cockman et al., 2000) . Moreover, these transcription factors can be stabilized and activated under hypoxic conditions, or by growth factor stimulation in both normal physiological conditions or pathological situations such as cancer (Shweiki et al., 1992; Jiang et al., 1997; Maxwell et al., 1999; Pal et al., 2001; Chung et al., 2004; Datta et al., 2004) . However, transcriptional control of VPF/VEGF is not the only regulator of VPF/VEGF synthesis; mRNA stability also plays a major role in the regulation of VPF/VEGF expression (Levy et al., 1996b; Claffey et al., 1998; Dibbens et al., 1999; Goldberg-Cohen et al., 2002) .
Generally, mRNA degradation is a tightly regulated process dependent on specific cis-acting sequences and trans-acting factors Bevilacqua et al., 2003) . One important example of a specific cisacting element is the adenylate-and uridylate-rich (AUrich) element found in the 3 0 untranslated region (UTR) (Shaw and Kamen, 1986) . So far, it is the most widespread and efficient determinant of RNA stability or instability among those characterized in mammalian cells. When present in multiple copies, the pentameric AUUUA or the heptameric UAUUUAU have a destabilizing role (Shaw and Kamen, 1986; Brennan et al., 2000) . The AU-rich elements (ARE) are potent stimulators for decapping and deadenylation, processes required for mediating mRNA turnover in mammalian cells. Several transactivating RNA-binding factors recognize the AU-rich cis-element. Some of the known AU-binding proteins are AUF1 (heterogeneous nuclear ribonucleoprotein), Tristetraprolin (TTP), KH-type splicing regulatory protein (KSRP), NF90, TIA-1, and HuR Chen et al., 2001; Blackshear, 2002; Shim et al., 2002; Zhang et al., 2002; Gherzi et al., 2004; Raineri et al., 2004; Wilusz and Wilusz, 2004) . Among all the ARE-binding proteins, HuR and TTP are the best-studied examples in vivo. TTP, like many other ARE-binding proteins, helps destabilize mRNA, whereas HuR stabilizes ARE-containing mRNA and is thus considered to be a unique member of this group. Although the detailed molecular mechanism of ARE-binding protein-mediated RNA degradation is not completely understood, the present hypothesis is that a specific conformation is attained when one or more of these factors bind to the AU-rich region of the mRNA. This complex is then recognized by the enzymatic machinery to target it for degradation. This enzymatic machinery is a multi-subunit protein complex known as the exosome. Upon substrate recognition, one or more enzymes of the exosome are selectively and allosterically activated, leading to the degradation of a given mRNA (Bevilacqua et al., 2003) . The mechanism in which HuR antagonizes this destabilizing effect remains elusive, but it is possible that HuR displaces destabilizing AREbinding proteins such as TTP and AUF1, leading to stabilization (Chen et al., 2002) .
Although little is known about the mechanism of VPF/VEGF mRNA stability, studies from several laboratories have suggested that the 3 0 UTR of VPF/ VEGF mRNA is important for its stability (Levy et al., 1996b; Claffey et al., 1998; Dibbens et al., 1999; Goldberg-Cohen et al., 2002) . It has also been suggested that a 125 bp AU-rich stem loop structure at VPF/ VEGF 3 0 UTR is critical for VPF/VEGF mRNA stability (Claffey et al., 1998) . Goldberg-Cohen et al. first reported a 3 0 -untranslated region binding protein that binds VPF/VEGF mRNA and that may be responsible for its increase in transcription (Levy et al., 1996a, b) . Recently, Hu family RNA-binding protein HuR Bevilacqua et al., 2003) has been shown to bind the ARE present in the 3 0 -untranslated region of VPF/VEGF mRNA and increase its stability Myer et al., 1997; Fan and Steitz, 1998; Peng et al., 1998; Brennan et al., 2000; Chen et al., 2002; Lopez de Silanes et al., 2004) . A 40-bp functional HuR binding site in the 3 0 -untranslated region of VPF/VEGF mRNA has been identified (Goldberg-Cohen et al., 2002) . Although predominantly nuclear, HuR shuttles between the nucleus and cytoplasm via a novel shuttling sequence, HNS Gallouzi et al., 2000) . HuR's ability to shuttle has led to the suggestion that HuR may initially bind mRNA in the nucleus and accompany them into the cytoplasm, providing ongoing protection from the degradation machinery . It will be important to note that zinc-finger domain containing destabilizing protein, TIS11b (a family of RNA-binding proteins that include TIS11/TTPtristetraprolin and TIS11d) also bind to AU-rich region of VEGF mRNA and are responsible for its degradation (Ciais et al., 2004) . Therefore HuR's ability to displace TIS11b may be one of the mechanisms for VEGF mRNA stability. However, the detailed molecular mechanism by which HuR increases the stability of VPF/VEGF mRNA still remains unclear.
Von Hippel Lindau (VHL) is a tumor supressor gene located on chromosome 3p25-26 (Seizinger et al., 1988; Maher and Kaelin, 1997) . VHL homozygous knockout mice die in utero at days 10.5-12.5 of gestation with hemorrhage and neurosis (Gnarra et al., 1997) . Germ line mutations of this gene lead to VHL-associated diseases such as clear cell renal carcinoma, hemangioblastoma, pheochrocytoma and pancreatic cancer (Maher and Kaelin, 1997) . VHL has been shown to downregulate hypoxia inducible genes such as VPF/ VEGF and HIF-la (Seizinger et al., 1988; Maher and Kaelin, 1997; Maxwell et al., 1999) . It has been well documented that the VHL gene product can posttranscriptionally control VPF/VEGF mRNA (Gnarra et al., 1996; Iliopoulos et al., 1996; Levy et al., 1997; Pioli and Rigby, 2001) . Specifically, it has been shown that in the VHL-deficient renal cancer cell line 786-O, the half-life of VPF/VEGF mRNA decreases significantly when wild-type VHL is stably expressed (Iliopoulos et al., 1996) . This result clearly indicates a role for VHL in VPF/VEGF mRNA stability. The VHL gene encodes a 213 amino-acid long single polypeptide chain; the Nterminus or beta domain of VHL (1-150 aa) is rich in beta sheets, whereas the C-terminus is composed mainly of alpha helices and is known as the alpha domain (Stebbins et al., 1999) . There are mutational hot spots in both the beta and alpha domains of VHL that have been found in patients with VHL-associated diseases (Maher and Kaelin, 1997) . There is a region ranging from amino acid 155-181 that binds a protein called elongin C. Recent studies have shown that VHL, elongin C, and elongin B, along with a cullin family protein CUL2 and Rbx form a multiprotein complex with E3-type ubiquitin ligase activity. In this complex, VHL acts as an adaptor protein, binding target proteins and helping them to be polyubiquitinated and then subsequently degraded by the proteasome complex (Ohh et al., 2000; Ivan et al., 2001; Jaakkola et al., 2001) .
In this study, we have observed that the same elonginbinding domain is important for VPF/VEGF mRNA stability. VHL interacts very specifically with one of the RNA-binding domains (RRM1) of HuR and thus inhibits its function to stabilize VPF/VEGF mRNA. Notably, this interaction between VHL and HuR is also dependant on hypoxia.
Results
HuR is not degraded in the presence of VHL As both HuR and VHL are known to regulate VPF/ VEGF mRNA stability (Iliopoulos et al., 1996; Goldberg-Cohen et al., 2002) , we first tried to determine any functional co-relation between these two molecules in terms of VPF/VEGF mRNA stability. In the presence of VHL, the VPF/VEGF mRNA stability significantly decreases (Iliopoulos et al., 1996) . Thus, we reasoned that it might be possible for VHL to polyubiquitinate HuR and to promote its degradation by the proteasome complex. As such, we performed a Western blot experiment to detect the protein level of HuR in the whole cell extract of RCC 786-O cells (786-O-neo: an empty cassette, Neo, has been stably transfected) and in 786-O cells stably expressing VHL . No change in HuR protein levels were observed suggesting that HuR is not degraded in the presence of VHL (Figure 1a ).
HuR associates with VHL in renal cancer cell line that stably expresses VHL protein
Interestingly, we observed an association between VHL and HuR when we performed a co-IP experiment using anti-VHL antibody followed by Western blot with antiHuR antibody in the cell lysate of renal cancer cells that stably express VHL (Figure 1b ). These results indicate a possible functional interaction between these molecules. Figure 1c showed the amount of overexpressed VHL protein in the stably cloned VHL gene in 786-O cells.
C-terminal domain of VHL interacts with HuR
To elucidate the nature of the interaction between HuR and VHL, we performed in vitro protein-binding assays with MBP-fused wild-type HuR and GST-fused wildtype VHL or its different deletion mutants. The in vitro binding assay suggests that VHL interacts directly with HuR at the C-terminal alpha domain of VHL (120-213) but not the N-terminal beta domain (1-122) ( Figure 2a ). The expression profile for wild-type and different GSTfused VHL fragments is presented in the lower panel of Figure 2a .
The elongin-binding site of VHL specifically interacts with HuR
The in vitro interaction study mentioned above was performed again using various deletion fragments of VHL, including the C-terminal elongin-binding site of VHL. The elongin-binding site of VHL (157-184 aa) has been found to be highly mutated in patients with VHL-associated diseases ( Figure 2b ). Two different point-mutated full length GST-fused VHL proteins were used in this binding study ( Figure 2b ). These point mutations are considered as hot spots for mutation at the elongin-binding sites. The results suggest that HuR binds at the elongin-binding site of VHL and, more importantly, that the specific amino acids in the elonginbinding sites that are considered hot spots for mutation are also important for the binding of HuR with VHL as HuR did not bind with the two specific point mutated VHL. The expression profile for GST-fused proteins is presented in the lower panel of Figure 2b .
RRM1 domain of HuR interacts with VHL
To determine the region of HuR that interacts with VHL, different deletion constructs of HuR were cloned into a pMAL-C2X vector. Full-length HuR has at least four functionally significant domains. The RRM1, two and three domains bind RNA, while the hinge region interacts with several proteins that are important for the translocation of HuR from the nucleus to the cytoplasm. The in vitro binding assay with different deletion fragments of MBP-fused HuR with wild-type VHL suggested that the RRM1 domain of MBP-HuR was the binding site for VHL (Figure 3a ). This is very unique, as most of the proteins that bind to HuR bind at the hinge region and regulate its translocation from the nucleus to the cytoplasm. The lower panel of Figure 3a showed the One construct contained only the RRM1 domain of HuR, while the other contained all domains except RRM1 (Figure 3b ). Both the constructs were fused with a FLAG epitope for their detection with anti-FLAG antibody. An immunoprecipitation experiment was performed with cell extracts from transfected 293T cells; anti-VHL antibody followed by Western blot with anti-FLAG antibody determined the importance of the RRM1 domain of HuR for its interaction with VHL ( Figure 3b) . 
Hypoxia decreases the association of HuR with VHL
Hypoxia increases the stability of VPF/VEGF mRNA. As such, we reasoned that when VHL is wild type, the Role of VHL on HuR-mediated VEGF mRNA stability K Datta et al association between HuR and VHL should decrease under hypoxic conditions as compared to under normoxic conditions. This is indeed the case in 786-O cells in which wild-type VHL is stably expressed (Figure 6a ). No change in HuR and VHL protein levels was observed under both normoxic and hypoxic conditions (Figure 6b and lower panel of Figure 6a ). The association between HuR and VHL also decreases under hypoxic conditions in 293T cells (Figure 6c ), although the protein levels of HuR and VHL remained unchanged under the same condition (Figure 6d and lower panel of Figure 6c ). Interestingly, when the RRM1 domain of HuR was transiently expressed in 293T cells, a decrease in the association between the RRM1 domain of HuR with wild-type VHL was observed under hypoxic conditions (Figure 6e ).
Taken together, the results presented above suggest an important role for the elongin-binding domain of VHL and the RRM1 domain of HuR in regulating VPF/VEGF mRNA stability. 
Discussion
The highly angiogenic phenotype of renal cell carcinoma (RCC) may be attributed to the abnormally high levels of the angiogenic growth factor, VPF/VEGF, that are often associated with this type of cancer (Shi and Siemann, 2002) . Several studies have shown that mutations in the tumor suppressor gene VHL (often mutated in clear cell RCC) lead to an increase in VPF/ VEGF mRNA levels (Seizinger et al., 1988; Maher and Kaelin, 1997) . Previous studies have shown that VHL regulates VPF/VEGF mRNA both transcriptionally and posttranscriptionally (Gnarra et al., 1996; Iliopoulos et al., 1996; Levy et al., 1997; Mukhopadhyay et al., 1997; Maxwell et al., 1999; Ivan et al., 2001; Pioli and Rigby, 2001) . Although the role of VHL in the transcriptional regulation of VPF/VEGF has been well studied, the mechanism for VHL regulation of VPF/ VEGF mRNA stability has been, at best, poorly understood. In this study, we provide evidence in favor of a specific mechanism by which VHL may regulate VPF/VEGF mRNA stability. We have observed that HuR and VHL are present in the same immunocomplex in renal cancer cell lines stably expressing VHL. Our in vitro interaction studies with different GST-fused deletion mutants of VHL proteins and MBP-fused HuR suggest that HuR binds specifically to the C-terminal elongin-binding domain of VHL. Strikingly, we also demonstrate that two amino acids frequently mutated in Role of VHL on HuR-mediated VEGF mRNA stability K Datta et al the VHL elongin-binding domain of RCC patients are critical for VHL interaction with HuR. Next, the results of our binding studies using different deletion fragments of HuR with wild-type VHL suggest that VHL binds specifically to one of the RNA-binding domains (RRM1) of HuR. The importance of the elonginbinding domain of VHL and the RRM1 domain of HuR for VPF/VEGF mRNA stability has also been demonstrated by Actinomycin D experiment. We believe Delta-RRM1-HuR is acting in a dominant-negative way of wt-HuR function. It has been previously reported that all the three RRM domains of HuR (RRM1, RRM2 and RRM3) bind the AU-rich sequence and poly-(A) containing mRNA . RRM1 and RRM2 bind the AU-rich sequence and RRM3 binds the poly-(A) sequence. It has also been observed that HuR can displace other destabilizing ARE-BPs, for example, tristetraproline and hnRNPD, leading to stabilization (Chen et al., 2002) . The interaction of all the three RNA-binding domains of HuR is important for its tight binding to the mRNA leading to the displacement of destabilizing ARE-BPs. Therefore, Delta-RRM1-HuR although able to bind mRNA binds with less affinity compared to the wild type. As a result, the overexpressed Delta-RRM1-HuR can compete with endogenous wt-HuR for the binding with the 3 0 UTR of VEGF mRNA but will not be able to displace the destabilizing ARE-Bps like TIS11b (Ciais et al., 2004) as efficiently as wild type. Thus, in the presence of overexpressed Delta-RRM1-HuR, we have observed a decrease in VEGF mRNA stability. The observation that less binding of HuR to the VPF/VEGF mRNA in the presence of VHL offers a mechanistic explanation of how VHL inhibits the HuR function and expedites the VPF/VEGF mRNA degradation. It will be interesting to determine whether by binding with RRM1 domain of HuR, VHL facilitates the entry of destabilizing factors like TIS1 lb to the 3 0 UTR of VEGF mRNA. In a recent report, Galban et al. (2003) demonstrated that the nucleus to cytoplasm translocation of HuR was regulated by VHL. Several reports suggested that the hinge region of HuR was the binding site of all the proteins responsible for its nucleus to cytoplasm translocation. Interestingly, we did not observe any binding of VHL to the hinge region of HuR. Again, we did not detect any difference in HuR protein amount in the cytoplasmic fractions of VHL and Neo cells, which was expected if the translocation of HuR was regulated by VHL. Further experiments are required to resolve this controversy. Currently, we can at least claim a parallel inhibitory mechanism of VHL of HuR function. Finally, we have shown that the interaction between HuR and VHL is dependant on oxygen concentration. Under hypoxic conditions, there is less interaction between these two molecules; this finding is consistent with the previous finding that, under normal physiological conditions, hypoxia increases mRNA stability. Taken together, our observations offer an explanation as to why VPF/VEGF-A mRNA is stable under normoxic conditons in RCC. Mutations in the VHL especially in the elongin-binding domain prevent its inhibitory interaction with the RRM1 RNA-binding domain of HuR. This in turn allows HuR to interact with and stabilize VPF/VEGF mRNA at its binding site in the 3 0 UTR, even under normoxic conditions.
Materials and methods
Cloning of MBP-fused full-length and different deletion constructs of HuR into pMAL-C2X
The full-length and different deletion constructs of HuR were PCR amplified using pcDNA3-HuR as the template and cloned into pMAL-C2X (New England Biolabs) at the restriction sites EcoBI (5 0 end) and HindIII (3 0 end). The following are the PCR primers for the full-length and different deletion constructs of HuR:
Full-length HuR: 5 0 -GCTAGAATTCATGCTTAATGGT TATGA-3 0 (forward) and 5 0 -GACAAGCTTTTATTTGT GGGACTTGTTGGT-3 0 (reverse). RRM1 (lackingRRM3, the hinge region, andRRM2): 5 0 -GCT AGAATTCATGCTTAATGGTTATGA-3 0 (forward) and 5 0 -GACAAGCTTTTATGAGCTCGGGCGAGCATACG ACAC-3 0 (reverse). DRRM1 (lacking N-terminus andRRM1): 5 0 -GCTAGAATT CATGGAGGTGATCAAAGACGCCAACTTG-3 0 (forward) and 5 0 -GCTAGAATTCATGAGAACGAATTTGATCGT CAACTAC-3 0 (reverse).
Another set of HuR plasmids was cloned into pCMV-Tag2B (New England Biolabs) vector at the EcoRI (5 0 end) and XhoI (3 0 end) restriction sites. PCR primers used to clone the deletion fragments of HuR were as follows:
DRRM3-hinge-RRM2-pCMV-Tag2B (lacking of RRM3, the hinge region, andRRM2): 5 0 -GGAAATCATGTCTAAT GGTTAT-3 0 (forward) and 5 0 -CCGCTCGAGGCTCGG GC GAGCATACGA-3 0 (reverse) DN-terminus-RRM1-pCMV-TagB (lacking of the N-terminus and RRM1): 5 0 -GGAATT CATGGAGGTGATCAAA GAC-3 0 (forward) and 5 0 -CCGCTCGAGTTAGTGGGAC TT GTTG-3 0 (reverse).
The elongin-binding site of VHL (155-187 amino acids) was amplified using primers that contain EcoRI (upstream) and HindIII (downstream) restriction sites. The full-length VHL expression plasmid was used as the template. After PCR amplification, the products were digested and cloned into pCMV-Tag2A (New England Biolabs). Oligonucleotides used to clone pCMV-Tag2A/VHL were as follows: 
Transfection
Approximately 20 h prior to transfection 1.0 Â 10 6. 293T cells were seeded onto 100 mm dishes and 2-3 Â 10 5 cells/60 mm dishes. Cells were transiently transfected with deletion mutants of HuR by the calcium-phosphate precipitation method. The expression was normalized with a control empty expression vector. Approximately 48 h after transfection cells were harvested in NP-40 lysis buffer [50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1%NP-4O, 1 mM Na 3 V0 4 , 2 mM EGTA and protease inhibitor tablet (Roche Molecular Biochemical)] followed by centrifugation at 14 000 rpm for 10 min.
Immunoprecipitation and Western blot analysis
Cells were washed twice with cold PBS, lysed with ice cold NP-40 lysis buffer, incubated for 10 min on ice and centrifuged at 14 000 rpm for 10 min at 41C. Immunoprecipitations were carried out by adding 4 mg of anti-VHL antibody (BD Pharmingen) to the cell lysates and incubating for 2 h at 41C on a rotar. Immunocomplexes were pulled down with protein A-sepharose beads (Pharmacia). Beads were washed three times with NP-40 lysis buffer and subjected to SDS-PAGE. Blots were probed with mouse monoclonal anti-HuR antibody (Molecular Probes) at 20 mg/10 ml of blocking buffer (5% W/V nonfat milk in TBST (150 mM NaCl, 10 mM Tris-HC1, pH 8.0, and 0.1% V/V Tween 20)). Horseradish peroxidase -conjugate secondary antibody was used at 1 : 1000 dilution in the same blocking buffer; chemilumenescent substrate used was for subsequent detection.
In vitro binding assay GST pull-down assays were performed as follows. In brief, GST fusion proteins were expressed in Escherichia coli strain BL21(DE3) (Stratagene). Cell pellets were sonicated in binding buffer (20 mM Tris-HCl, pH 7.5, 150 mM KC1, 1 mM EDTA, 0.5% Nonidet P-40). Fusion proteins were mixed with glutathione-sepharose beads (Pharmacia) and washed Â 3 with binding buffer containing 0.05% SDS. Beads were mixed with 50 ng purified protein, either MBP-fused WT HuR or its deletion mutants and bovine serum albumin (5 mg) in binding buffer, incubated with agitation for 1 h in the cold room and washed Â 4 with binding buffer. Bound proteins were resolved by SDS-PAGE and Western blotting.
VPF/VEGF mRNA stability experiments
Subconfluent cells were exposed to 5 mg/ml actinomycin D (Sigma) from 0 to 8 h. RNA was collected from the following cell lines and subjected to real-time PCR using primers specific for VPF/VEGF-A: 293T cells transiently transfected with either deletion mutant of HuR or deletion mutant of VHL and 786-O cells stably expressing either the deleted fragments of HuR or the empty vector.
RNA probe synthesis
Labeled RNA probe was generated by in vitro transcription using T7 RNA polymerase (Riboprobe in vitro transcription system; Promega, Mannheim, Germany) and XbaI linearized pcDNA3 (Invitrogen, Karlsruhe, Germany) plasmid containing 47 nt AU element (Goldberg-Cohen et al.,. 2002) (sense:  5  0 -CTT TCT TAT TTG TAC TGT TTT TTT TTT TTG TTT TGT TTT TCT GTG TG-3 0 ; antisense: 5 0 -GAA AGA ATA AAC ATG ACA AAA AAA AAA AAC AAA ACA AAA AGA CAC AC-3 0 ) cloned at the BamHI site used as template. Sequence of nonspecific probe was generated using HindIII linearized pcDNA3 (Invitrogen) containing 47 nt AU element with SP6 RNA polymerase. 50 m1 of transcription reaction contained 50 units of T7/56 units of SP6 polymerase, 50 units of ribonuclease inhibitor, 500 mM of each ATP, CTP and GTP, 12 mM of UTP, 125 mCi of a-32P UTP (3000 Ci/mmol, Perkin Elmer), 10 mM of DTT. Transcription reaction was carried out in 1 Â transcription buffer at 371C for 1 h. RNA probes were extracted with phenol/chloroform and ethanol was precipitated. Unincorporated nucleotides were removed using Sephadex G-25 mini Quick Spin RNA columns (Roche, Mannheim, Germany).
RNA-EMSA
In gel retardation assay, 8 mg of cell-fractionated protein (786-O neo and VHL) was incubated for 30 min at 371C in binding buffer (10 mM HEPES pH 7.6, 5 mM MgCl 2 , 40 mM KC1, 1 mM DTT, 5% glycerol, 5 mg/ml heparin) with 5 pmol of RNA probe in a final volume of 25 ml. To show the interaction between HuR protein and RNA transcript samples were incubated with anti-HuR antibody and IgG. Then 7 m1 of loading buffer (80% glycerol, 0.1% bromophenol blue in 50 mM Tris-HCl) was added and electrophoresed at 100 V for 1 h on 4% polyacrylamide gel (prerun at 100 V for 0.5 h) containing 44 mM Tris-Hcl pH 8.3, 44 mM boric acid, 1 mM EDTA, 4% acrylamide-bisacrylamide (29 : 1) and 2.5% glycerol. Finally, the gel was dried under vacuum and exposed to Kodak X-OMAT AR films at À801C.
